Company Profile

Apollo Hospitals is gearing up to give one million vaccines a day once it is available across India through its hospitals, clinics, health centres, pharmacies and Apollo 24/7. Apollo 24/7 is doing a survey asking customers whether they will take the vaccine and also making them register.

Apollo Hospitals Enterprise owns and operates chain of multi-specialty hospitals. It offers the services in the area of cardiology, cardiothoracic, orthopedics and joint replacement, spine surgery, oncology, etc.

Apollo Hospitals Enterprise is currently trading at Rs. 2257.05, up by 15.45 points or 0.69% from its previous closing of Rs. 2241.60 on the BSE.

The scrip opened at Rs. 2240.15 and has touched a high and low of Rs. 2294.95 and Rs. 2240.15 respectively. So far 39841 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2422.35 on 24-Nov-2020 and a 52 week low of Rs. 1047.45 on 31-Mar-2020.

Last one week high and low of the scrip stood at Rs. 2422.35 and Rs. 2237.00 respectively. The current market cap of the company is Rs. 31424.90 crore.

The promoters holding in the company stood at 30.82%, while Institutions and Non-Institutions held 62.52% and 6.43% respectively.

Apollo Hospitals is gearing up to give one million vaccines a day once it is available across India through its hospitals, clinics, health centres, pharmacies and Apollo 24/7. Apollo 24/7 is doing a survey asking customers whether they will take the vaccine and also making them register.

Apollo Hospitals Enterprise owns and operates chain of multi-specialty hospitals. It offers the services in the area of cardiology, cardiothoracic, orthopedics and joint replacement, spine surgery, oncology, etc.

Apollo Hospitals Group has collaborated with Tata Medical and Diagnostics (TataMD) to introduce 'TataMD CHECK' diagnostic test for COVID-19 in the country, which will provide faster results. Apollo Hospitals along with its subsidiary Apollo Diagnostics will offer the Tata MD CHECK testing in the national capital region (NCR) from the first week of December 2020 and thereafter, it will be rolled out across all major metros in the country.

TataMD CHECK is a COVID-19 diagnostic test based on the DNA genome editing tool CRISPR Cas-9 and has been approved by Indian Council of Medical Research and Drug Controller General of India (DCGI).  The use of CRISPR-Cas9 Technology ensures quicker results due to a more agile process and AI-based automated result detection methodology.

Apollo Hospitals Enterprise owns and operates chain of multi-specialty hospitals. It offers the services in the area of cardiology, cardiothoracic, orthopedics and joint replacement, spine surgery, oncology, etc.

Apollo Hospitals is currently trading at Rs. 2381.25, up by 82.85 points or 3.60% from its previous closing of Rs. 2298.40 on the BSE.

The scrip opened at Rs. 2325.00 and has touched a high and low of Rs. 2393.95 and Rs. 2325.00 respectively. So far 22518 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2414.85 on 19-Nov-2020 and a 52 week low of Rs. 1047.45 on 31-Mar-2020.

Last one week high and low of the scrip stood at Rs. 2414.85 and Rs. 2267.10 respectively. The current market cap of the company is Rs. 33016.49 crore.

The promoters holding in the company stood at 30.82%, while Institutions and Non-Institutions held 62.52% and 6.43% respectively.

Apollo Hospitals Group has collaborated with Tata Medical and Diagnostics (TataMD) to introduce 'TataMD CHECK' diagnostic test for COVID-19 in the country, which will provide faster results. Apollo Hospitals along with its subsidiary Apollo Diagnostics will offer the Tata MD CHECK testing in the national capital region (NCR) from the first week of December 2020 and thereafter, it will be rolled out across all major metros in the country.

TataMD CHECK is a COVID-19 diagnostic test based on the DNA genome editing tool CRISPR Cas-9 and has been approved by Indian Council of Medical Research and Drug Controller General of India (DCGI).  The use of CRISPR-Cas9 Technology ensures quicker results due to a more agile process and AI-based automated result detection methodology.

Apollo Hospitals Enterprise owns and operates chain of multi-specialty hospitals. It offers the services in the area of cardiology, cardiothoracic, orthopedics and joint replacement, spine surgery, oncology, etc.

Apollo Hospitals Enterprise has reported results for the second quarter ended September 30, 2020.

The company has reported 63.77% fall in its net profit at Rs 32.82 crore for the quarter under review as compared to net profit of Rs 90.60 crore for the same quarter in the previous year. Total income of the company decreased by 1.96% at Rs 2,419.24 crore for Q2FY21 as compared Rs 2,467.52 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 30.11% in its net profit attributable to owners at Rs 60.27 crore for the quarter under review as compared to net profit at Rs 86.24 crore for the same quarter in the previous year. Total income of the company decreased by 2.54% at Rs 2,772.04 crore for Q2FY21 as compared Rs 2,844.25 crore for the corresponding quarter previous year.